Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera (Q36938773)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 13 October 2009

Language	Label	Description	Also known as
English	Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera	scientific article published on 13 October 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

polycythemia vera

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

2

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

5

object named as

Zeev Estrov

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Srdan Verstovsek

11

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Jorge Eduardo Cortes

10

object named as

Jorge Cortes

1 reference

Europe PubMed Central

17 August 2017

PMC publication ID

Gautam Borthakur

8

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

17 August 2017

PMC publication ID

6

object named as

Sherry Pierce

1 reference

Europe PubMed Central

17 August 2017

PMC publication ID

Marina Konopleva

9

object named as

Marina Konopleva

1 reference

Europe PubMed Central

17 August 2017

PMC publication ID

Rajyalakshmi Luthra

4

object named as

Rajyalakshmi Luthra

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Mary Ann Richie

7

object named as

Mary Ann Richie

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Taghi Manshouri

3

object named as

Taghi Manshouri

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

author name string

Alfonso Quintás-Cardama

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

language of work or name

0 references

publication date

13 October 2009

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

32

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

5418-5424

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Identification of an acquired JAK2 mutation in polycythemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

29 September 2017

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

4 September 2018

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

4 September 2018

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

4 September 2018

Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

4 September 2018

Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

4 September 2018

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881362

4 December 2018

Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826111

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826111

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826111

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826111

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826111

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826111

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826111

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826111

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.23.6075

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36938773&oldid=2117033818"